Peringatan Keamanan

Oral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.

Nizatidine

DB00585

small molecule approved

Deskripsi

A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

Struktur Molekul 2D

Berat 331.45
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1-2 hours
Volume Distribusi * 0.8 to 1.5 L/kg
Klirens (Clearance) * 40-60 L/h * 7 – 14 L/h [functionally anephric patients]

Absorpsi

Rapid (bioavailability of nizatidine exceeds 70%)

Metabolisme

Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol.
  • 2. Limit caffeine intake.
  • 3. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

494 Data
Atazanavir Nizatidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefditoren The serum concentration of Cefditoren can be decreased when it is combined with Nizatidine.
Dabigatran etexilate Nizatidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dabrafenib Nizatidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Erlotinib Nizatidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazopanib Nizatidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Riociguat Nizatidine can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.
Benzylpenicilloyl polylysine Nizatidine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Nizatidine.
Hyaluronidase (ovine) The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Nizatidine.
Hyaluronidase (human recombinant) The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Nizatidine.
Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.
Bosutinib Nizatidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefpodoxime Nizatidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cefuroxime Nizatidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dasatinib Nizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Delavirdine Nizatidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexmethylphenidate The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Nizatidine.
Amprenavir Nizatidine can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fosamprenavir Nizatidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gefitinib Nizatidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Indinavir Nizatidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Itraconazole Nizatidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ledipasvir Nizatidine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Nizatidine.
Nelfinavir Nizatidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nilotinib Nizatidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rilpivirine Nizatidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Risedronic acid Nizatidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.
Saquinavir Nizatidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dipyridamole The therapeutic efficacy of Nizatidine can be decreased when used in combination with Dipyridamole.
Ephedrine Nizatidine may increase the neuromuscular blocking activities of Ephedrine.
Bambuterol Nizatidine may increase the neuromuscular blocking activities of Bambuterol.
Clevidipine Nizatidine may increase the neuromuscular blocking activities of Clevidipine.
Sar9, Met (O2)11-Substance P Nizatidine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.
Moxisylyte Nizatidine may increase the neuromuscular blocking activities of Moxisylyte.
Propacetamol Nizatidine may increase the neuromuscular blocking activities of Propacetamol.
Procaine Nizatidine may increase the neuromuscular blocking activities of Procaine.
Cocaine Nizatidine may increase the neuromuscular blocking activities of Cocaine.
Trimethaphan Nizatidine may increase the neuromuscular blocking activities of Trimethaphan.
Doxacurium Nizatidine may increase the neuromuscular blocking activities of Doxacurium.
Chloroprocaine Nizatidine may increase the neuromuscular blocking activities of Chloroprocaine.
Tubocurarine Nizatidine may increase the neuromuscular blocking activities of Tubocurarine.
Aclidinium Nizatidine may increase the neuromuscular blocking activities of Aclidinium.
Butyrylthiocholine Nizatidine may increase the neuromuscular blocking activities of Butyrylthiocholine.
Mirabegron Nizatidine may increase the neuromuscular blocking activities of Mirabegron.
Oxybuprocaine Nizatidine may increase the neuromuscular blocking activities of Oxybuprocaine.
Benzonatate Nizatidine may increase the neuromuscular blocking activities of Benzonatate.
Levothyroxine Nizatidine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Succinylcholine The metabolism of Succinylcholine can be decreased when combined with Nizatidine.
Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Nizatidine.
Captopril Nizatidine can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.
Rifampin Nizatidine can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Memantine Nizatidine may decrease the excretion rate of Memantine which could result in a higher serum level.
Sulpiride The therapeutic efficacy of Sulpiride can be increased when used in combination with Nizatidine.
Mesalazine Nizatidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acid Nizatidine can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tolevamer The therapeutic efficacy of Tolevamer can be decreased when used in combination with Nizatidine.
Amphetamine Amphetamine may decrease the sedative activities of Nizatidine.
Phentermine Phentermine may decrease the sedative activities of Nizatidine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Nizatidine.
Benzphetamine Benzphetamine may decrease the sedative activities of Nizatidine.
Diethylpropion Diethylpropion may decrease the sedative activities of Nizatidine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Nizatidine.
Mephentermine Mephentermine may decrease the sedative activities of Nizatidine.
MMDA MMDA may decrease the sedative activities of Nizatidine.
Midomafetamine Midomafetamine may decrease the sedative activities of Nizatidine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Nizatidine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Nizatidine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Nizatidine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Nizatidine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Nizatidine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Nizatidine.
Metamfetamine Metamfetamine may decrease the sedative activities of Nizatidine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Nizatidine.
Ritobegron Ritobegron may decrease the sedative activities of Nizatidine.
Mephedrone Mephedrone may decrease the sedative activities of Nizatidine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Nizatidine.
Gepefrine Gepefrine may decrease the sedative activities of Nizatidine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Nizatidine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Nizatidine.
Cysteamine The bioavailability of Cysteamine can be decreased when combined with Nizatidine.
Ketoconazole Nizatidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Nizatidine.
Trospium The therapeutic efficacy of Trospium can be decreased when used in combination with Nizatidine.
Oxyphenonium The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Nizatidine.
Butabarbital The therapeutic efficacy of Butabarbital can be decreased when used in combination with Nizatidine.
Butalbital The therapeutic efficacy of Butalbital can be decreased when used in combination with Nizatidine.
Benzatropine The therapeutic efficacy of Benzatropine can be decreased when used in combination with Nizatidine.
Ziprasidone The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Nizatidine.
Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Nizatidine.
Talbutal The therapeutic efficacy of Talbutal can be decreased when used in combination with Nizatidine.
Pentobarbital The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Nizatidine.
Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Nizatidine.
Ipratropium The therapeutic efficacy of Ipratropium can be decreased when used in combination with Nizatidine.
Methadone The therapeutic efficacy of Methadone can be decreased when used in combination with Nizatidine.
Olanzapine The therapeutic efficacy of Olanzapine can be decreased when used in combination with Nizatidine.
Metixene The therapeutic efficacy of Metixene can be decreased when used in combination with Nizatidine.
Terfenadine The therapeutic efficacy of Terfenadine can be decreased when used in combination with Nizatidine.
Buclizine The therapeutic efficacy of Buclizine can be decreased when used in combination with Nizatidine.

Target Protein

Histamine H2 receptor HRH2

Referensi & Sumber

Synthesis reference: Charles W. Ryan, Bruce A. Slomski, "Synthesis of nizatidine intermediate." U.S. Patent US4777260, issued June, 1983.

Contoh Produk & Brand

Produk: 66 • International brands: 2
Produk
  • Apo-nizatidine
    Capsule • 150 mg • Oral • Canada • Generic • Approved
  • Apo-nizatidine
    Capsule • 300 mg • Oral • Canada • Generic • Approved
  • Axid
    Capsule • 150 mg/1 • Oral • US • Approved
  • Axid
    Capsule • 300 mg/1 • Oral • US • Approved
  • Axid
    Capsule • 150 mg/1 • Oral • US • Approved
  • Axid
    Capsule • 300 mg/1 • Oral • US • Approved
  • Axid
    Solution • 15 mg/1mL • Oral • US • Approved
  • Axid
    Solution • 15 mg/1mL • Oral • US • Approved
Menampilkan 8 dari 66 produk.
International Brands
  • Acinon
  • Tazac — Eli Lilly

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul